NovaBridge Biosciences (NBP) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, NBP scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 7 out of 20, reflecting a ROIC of -35% and an FCF yield of 0%, which indicates the business is not currently generating returns on invested capital or free cash flow. The whale/13F flow pillar scores 6 out of 20, pointing to institutional accumulation and options positioning that is weak relative to the maximum. The insider conviction pillar scores 5 out of 20, based on SEC Form 4 and Congressional PTR cluster flow. The macro regime fit pillar scores 10 out of 20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 10 out of 20, reflecting an Altman Z of 2.5, a Piotroski F of 1/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the upside case rests on the balance-sheet cushion and the recent licensing catalyst rather than on current profitability. The valuation tradeoff is stark: with no reported revenue in FY 2025 and an operating loss of $-94.3M, traditional earnings-based valuation is not applicable from the source data, and the stock's market capitalization of $139.6M sits against reported cash of $210.6M, a relationship an investor should examine directly. The weakest pillars (fundamental cash engine and insider conviction) are the ones most tied to whether the company can convert its cash into durable operations, so the investment case depends heavily on that conversion. This analysis is educational and is not personalized financial advice.

Per the SEC financials, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Reported cash rose from $68.3M in FY 2024 to $210.6M in FY 2025 while operating losses widened from $-51.4M to $-94.3M. The Piotroski score of 1/9 signals weak financial-quality signals across the nine tests, and the Altman Z of 2.5 is reported within the source data without a stated zone classification.

Per the recent news and catalysts feed, the most significant item is a CATALYST-tagged (GREEN) report that the company's subsidiary Visara gains exclusive rights outside Greater China to investigational eye drug VIS-102. The remaining five items are MARKET WIRE (YELLOW) reports covering price action and institutional positioning, including a headline noting a finance chief with over 25 years in biotech and investing is set to join NovaBridge, and a headline noting shares edging higher to $1.25 as buyers test $1.31 resistance. The source for that price-action item is labeled as an unrelated website, so its reliability as a technical signal is limited. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

Risk watch items include the sustained operating losses, the 52-week trading range of $1.15 - $5.19 with the current price of 1.16 near the low end, and the -3.33% daily change.

• What is the company's revenue model, and what specific products or licensed assets generate or are expected to generate revenue beyond the $0.6M reported in FY 2023?
• What is the cash runway implied by the reported $210.6M in cash against the FY 2025 operating loss of $-94.3M, and what drove the increase in cash from $68.3M in FY 2024?
• What are the terms, counterparties, and milestones of the VIS-102 exclusive rights arrangement, and how material is it to the balance sheet?
• What is the company's debt position, given that the debt line is reported as N/A while Debt/Equity is cited as 0.5?
• Who are the institutional and insider holders, and what are the analyst ratings and price targets, given that both sections are empty in the source data?